Sponsors Can Expect REMS Discussions As Early As Phase II, FDA Says

Though REMS requirements caused longer reviews in 2008, FDA Deputy Director Office of New Drugs Sandra Kweder said the agency expects "we will be doing this better and it will not affect PDUFA deadlines" going forward.